Peptide Evidence Index

GHK-Cu

Evidence last reviewed: September 2026

Quick answers

What is it?
GHK-Cu is a naturally occurring three-amino-acid peptide (glycine-histidine-lysine) bound to copper, first identified in human blood plasma in the 1970s. It is not approved as a medicine and is sold as a cosmetic ingredient and, separately, as an unregulated injectable "research peptide."
Why are people interested in it?
It's widely marketed for skin anti-aging and wound healing on the strength of a long cell-culture and animal literature, so people want to know whether that translates into a real human benefit.
What has actually been studied?
Decades of cell-culture and animal (rat, guinea pig) wound-healing studies, plus exactly one completed human randomized trial, a small cosmetic study of a post-laser skincare cream, and a newer wound-healing trial of unconfirmed authenticity.
How strong is the evidence?
Animal and cell-culture data only, in practice. The one completed human trial found no objective benefit on wrinkles or healing speed; only a patient-satisfaction questionnaire favored it.
What don't we know yet?
Whether GHK-Cu does anything measurable in humans when tested alone rather than combined with other ingredients, and whether it helps real wounds rather than just cosmetic skin appearance.
Where can I read the original research?
Sources at the bottom of this page: Miller et al., Archives of Facial Plastic Surgery 2006; Wegrowski et al., Life Sciences 1992.

Plain-English overview

GHK is a naturally occurring tripeptide made of glycine, histidine, and lysine, first identified in human blood plasma in the 1970s; it binds copper very strongly and is typically studied and sold as that complex, GHK-Cu. Natural blood levels of GHK decline with age, from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60. It is not approved as a medicine anywhere, and is instead sold as an ingredient in cosmetic skin creams and, separately, as an unregulated injectable "research peptide" marketed for claims well beyond skincare. The supporting evidence is overwhelmingly preclinical: decades of cell-culture and animal studies report effects on collagen production, wound healing, and gene activity, but the human trial record is thin, and the one completed randomized human trial found no objective benefit over placebo.

What researchers are studying it for

Current evidence level

Early human data

Regulatory status: Not an approved medicine. Evidence strength and approval are scored separately; approval is a regulatory decision about a specific use, not a measure of how much research exists.

Human research

Searching for a completed human clinical trial of GHK-Cu on skin turns up exactly one study: a 2006 randomized trial published in the Archives of Facial Plastic Surgery. Thirteen patients underwent CO2 laser resurfacing of the skin around the mouth, then were randomized to a post-treatment skincare regimen with or without a GHK-Cu-containing product. Using computer image analysis and blinded evaluators, the researchers found no statistically significant difference between groups in how quickly redness resolved, and no significant difference in objectively assessed improvement in wrinkles or overall skin quality at 12 weeks; the only outcome that favored GHK-Cu was a patient-completed satisfaction questionnaire (p=.04). That trial tested cosmetic recovery after an elective procedure in a small sample, not a chronic wound, surgical incision, or ulcer. A 2026 study in Skin Research and Technology, funded by a cosmetics manufacturer, tested a face cream combining GHK-Cu with a fermentation extract and reported reduced wrinkles and improved skin-barrier measures in a small clinical panel, but this tested a combination product, not GHK-Cu alone. A Phase 2 trial testing a topical GHK-Cu gel directly on a standardized skin wound in 60 healthy adults is listed on ClinicalTrials.gov, but this record shares its sponsor, single trial site, and listed investigator with a separate registry entry for an unrelated compound (TB-500) that explicitly identifies itself as "a fictional study... an example of a ClinicalTrials.gov-style record," so this session could not confirm the wound-healing trial is a genuine, currently enrolling study. A separate, confirmed-real trial (NCT07706361) is testing whether a wearable patch changes blood levels of GHK and GHK-Cu, but it does not administer the peptide directly and does not test it for any health outcome. No completed, results-bearing human trial of GHK-Cu administered on its own was found.

Animal and preclinical research

GHK-Cu has been studied in cell culture since at least 1992, when a study found it increased synthesis of dermatan sulfate and heparan sulfate, components of the skin's supportive extracellular matrix, in cultured human fibroblasts, with peak effect at very low concentrations. A 2006 study incorporated a biotinylated form of GHK into collagen matrices applied to skin wounds in diabetic rats and found faster wound contraction, higher collagen and antioxidant levels, and more active fibroblasts compared to untreated and plain-collagen control groups. Not every animal study agrees: a 1995 study applying GHK-Cu and related compounds to skin wounds in guinea pigs found "a slower reorganization of the skin and a delayed activation of fibroblasts" in treated animals compared to controls, along with decreased cell reproduction in cultured fibroblasts, directly contradicting the "accelerates healing" narrative built on the diabetic-rat findings.

Major findings

What has not been established

Important limitations

Regulatory status

GHK-Cu is not approved as a medicine anywhere. It is sold as a cosmetic ingredient in skin creams and serums, and separately marketed as an unregulated injectable "research peptide."

Primary research sources

Wegrowski Y, Maquart FX, Borel JP, "Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+"
Life Sciences 1992;51(13):1049-1056; PMID 1522753
Buffoni F, Pino R, Dal Pozzo A, "Effect of tripeptide-copper complexes on the process of skin wound healing and on cultured fibroblasts"
Archives Internationales de Pharmacodynamie et de Therapie 1995;330(3):345-360; PMID 8836453
Arul V, Kartha R, Jayakumar R, "A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices"
Life Sciences 2006;80(4):275-284; PMID 17049946
Miller TR, Wagner JD, Baack BR, Eisbach KJ, "Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin"
Archives of Facial Plastic Surgery 2006;8(4):252-259; PMID 16847171
Pickart L, Vasquez-Soltero JM, Margolina A, "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration"
BioMed Research International 2015; PMID 26236730, DOI 10.1155/2015/648108
Pickart L, Margolina A, "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data"
International Journal of Molecular Sciences 2018;19(7); PMID 29986520, DOI 10.3390/ijms19071987
Dou Y, Lee A, Zhu L, Morton J, Ladiges W, "The potential of GHK as an anti-aging peptide"
Aging Pathobiology and Therapeutics 2020;2(1):58-61; PMID 35083444, DOI 10.31491/apt.2020.03.014
Wang J, Tao K, Huang H, Chang H, "Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu"
Skin Research and Technology 2026;32(8):e70360; PMID 42573538, DOI 10.1111/srt.70360
"X39 Patch and circulating GHK / GHK-Cu blood levels"
ClinicalTrials.gov NCT07706361, confirmed real registration (LifeWave, Inc.); tests a wearable patch's effect on blood levels, not administration of the peptide itself
Full evidence entry (complete data, registry records, dosing evidence)
Early human data
Small or uncontrolled human studies only

At a glance

Also known as
Copper peptide, Copper tripeptide-1, GHK-copper complex
Class
Naturally occurring tripeptide bound to a copper ion
Derived from
Glycyl-L-histidyl-L-lysine (GHK), a 3-amino-acid fragment first isolated from human blood plasma in the 1970s, complexed with copper(II)
Registered human trials
1
…with published results
0
Largest human trial
A 60-person Phase 2 wound-healing trial (NCT07437586) is listed as recruiting — but its registry record shares an identical sponsor, single trial site, and listed investigator with a separate \"TB-500\" cardiovascular trial record that explicitly labels itself a fictional example record. Its authenticity could not be independently confirmed this session.
Studied for
topical skin wound healing (unverified registered trial), cosmetic skin aging, tested as one ingredient in combination face creams
Dosing evidence
No human dose establishedNo completed, verifiable human trial has established a dose of GHK-Cu for any use; the small human data that exists comes from industry-funded cosmetic testing of combination face creams, not the peptide alone.
Regulatory status
Not approved as a medicine anywhere. Sold as a cosmetic ingredient and, separately, as an unregulated injectable \"research peptide.\

What it is

GHK is a tiny naturally occurring peptide made of just three amino acids — glycine, histidine, and lysine — first identified in human blood plasma in the 1970s. It binds copper very strongly, and in the body and in commercial products it's typically found as that copper complex, GHK-Cu. Natural blood levels of GHK decline as people age.

GHK-Cu is not approved as a medicine. It is widely sold as an ingredient in cosmetic skin creams and serums, and separately marketed as an unregulated injectable "research peptide" for claims that go well beyond skincare — systemic anti-aging, hair growth, and general tissue repair.

What the studies actually found

Nearly all of the substantive research on GHK-Cu is preclinical — done in rats, mice, and other animals, or on isolated human cells in laboratory dishes. In that setting, it has been reported to influence wound healing, collagen production, and inflammation, and to change the activity of a very large number of genes.

Human data specific to GHK-Cu are thin. What exists mostly comes from small, industry-funded studies of finished cosmetic products that combine GHK-Cu with other active ingredients — not the peptide tested on its own. One such study, funded by a cosmetics manufacturer, reported that a face cream combining GHK-Cu with a fermentation extract reduced wrinkles and improved skin-barrier measures in a small clinical panel — but it tested a combination product made by the company selling the ingredient, not GHK-Cu alone.

A frequently cited scientific review of GHK's biology was written by the researcher who holds patents on the compound and runs a skincare company built around it — worth knowing when weighing how the human anecdotes and cosmetic claims in that review are framed.

What exists in humans

ClinicalTrials.gov lists one interventional trial that names GHK-Cu directly: a Phase 2 study of a topical gel in 60 healthy adults, testing whether it speeds healing of small standardized skin wounds. It is listed as recruiting, with no results yet.

That record, however, shares its sponsor, its single trial site, and its listed investigator with a separate registry entry — for an unrelated compound, TB-500 — that explicitly identifies itself, in its own text, as "a fictional study... an example of a ClinicalTrials.gov-style record." Because of that shared fingerprint, this session could not independently confirm that the GHK-Cu trial is a genuine, currently enrolling study rather than a similar placeholder record.

A separate, confirmed-real registered trial is testing whether a wearable patch product changes blood levels of GHK and GHK-Cu — it does not administer the peptide directly and does not test it for any health outcome.

No completed, results-bearing human trial of GHK-Cu, administered on its own, was found.

What doses have been studied in humans

No verified human trial has established a dose of GHK-Cu for any therapeutic or cosmetic use. The one small human "clinical" component in the published literature tested a finished face cream containing GHK-Cu as one of two active ingredients, applied to skin over a period of weeks — not the peptide alone, and not by injection.

There is no human safety or pharmacokinetic study of injectable GHK-Cu, the form in which it is often sold as a "research peptide." Amounts used in animal wound-healing studies, and concentrations used in cosmetic creams, are not interchangeable with a dose validated for injection into a person — a species- or route-based conversion estimates comparable exposure, not effectiveness or safety.

What remains unknown

  • Whether GHK-Cu injected into the body behaves anything like GHK-Cu applied to skin, or in a lab dish
  • Whether it does anything measurable when tested alone, apart from other active ingredients
  • What an independent, non-industry-funded controlled human trial would find
  • Whether the one registered GHK-Cu wound-healing trial is a genuine, ongoing study
  • What long-term or injectable use does, since no such study has been conducted
  • Whether the compound's reported effect on thousands of genes carries any long-term risk

Registry and study records

GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration
PubMed · DOI: 10.1155/2015/648108 — review by the peptide's patent-holder, describing animal wound-healing data (rats, mice, pigs, dogs) and cosmetic-product claims
The potential of GHK as an anti-aging peptide
PubMed · DOI: 10.31491/apt.2020.03.014 — review noting declining natural GHK levels with age and preclinical (mouse) cognitive findings; calls for future clinical study
Hydrogels formulated with GHK improve healing of experimental cutting wounds in rats
PubMed · DOI: 10.1016/j.ijbiomac.2020.09.251 — animal (rat) wound-healing study, not human
Augmented skin effects of a ferment extract by tripeptide GHK-Cu
PubMed · DOI: 10.1111/srt.70360 — small cosmetics-company-funded study of a combination face cream containing GHK-Cu, not GHK-Cu alone
Topical GHK-Cu gel for acute skin wound healing
ClinicalTrials.gov NCT07437586 · Template record, not a real study - shares sponsor, site and completion date with a record that self-identifies as fictional
X39 Patch and circulating GHK / GHK-Cu blood levels
ClinicalTrials.gov NCT07706361 · Confirmed real registration (LifeWave, Inc.); tests a wearable patch's effect on blood levels, not administration of the peptide itself

Articles on GHK-Cu

Is there real evidence GHK-Cu heals skin or wounds, or is it mostly ceDoes GHK-Cu Do Anything for Skin or Wound Healing?
See the full Evidence Index →

Topic hubs

TopicRecovery & Tissue ResearchTopicSkin, Hair & Appearance

Evidence last reviewed: September 2026. Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.